Tivantinib for hepatocellular carcinoma

Bibliography

• Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced Hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400
   PubMed Web of Science ®Google Scholar
• Takayama H, LaRochelle WJ, Sharp R. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701-6
   PubMed Web of Science ®Google Scholar
• Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-54
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103
   PubMed Web of Science ®Google Scholar
• You H, Ding W, Dang H, et al. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011;54:879-89
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45
   PubMed Web of Science ®Google Scholar
• Suzuki K, Hayashi N, Yamada Y, et al. Expression of the c-Met protooncogene in human hepatocellular carcinoma. Hepatology 1994;20:1231-6
   PubMed Web of Science ®Google Scholar
• Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997;25:862-6
   PubMed Web of Science ®Google Scholar
• Osada S, Kanematsu M, Imai H, et al. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008;55:544-9
   PubMed Web of Science ®Google Scholar
• Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-95
   PubMed Web of Science ®Google Scholar
• Zhang SZ, Pan FY, Xu JF, et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005;4:1577-84
   PubMed Web of Science ®Google Scholar
• Salvi A, Arici B, Portolani N, et al. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol 2007;31:451-60
   PubMedGoogle Scholar
• Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-16
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57-67
   PubMed Web of Science ®Google Scholar
• Zhu AX, Ryoo BY, Yen CJ, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma after first-line therapy with sorafenib: results from the randomized Phase III REACH study. Ann Oncol 2014;25(Suppl5):1-41
   Google Scholar
• Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-53
   PubMed Web of Science ®Google Scholar
• Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011;286:20666-76
   PubMed Web of Science ®Google Scholar
• Calles A, Kwiatkowski N, Cammarata BK, et al. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol Oncol 2015;9:260-9
   PubMed Web of Science ®Google Scholar
• Basilico C, Pennacchietti S, Vigna E, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013;19:2381-92
   PubMed Web of Science ®Google Scholar
• Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013;73(10):3087-96
   PubMed Web of Science ®Google Scholar
• Aoyama A, Katayama R, Oh-hara T, et al. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance. Mol Cancer Ther 2014;13:2978-90
   PubMedGoogle Scholar
• Chen CR, Szwaya J, Rojnuckarinet A, et al. Combination studies of tyrosine kinase inhibitors (TKIs): assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinib [abstract 820]. AACR Annual Meeting 18-22, Denver (CO), USA: 18-22 April 2009
   Google Scholar
• Savage RE, Zhong C, Hall T, et al. In vitro ADME Properties of ARQ-197. Comparison to in vivo data [abstract 1291]. AACR Annual Meeting 2008, San Diego (CA), USA: 12-16 April 2008
   Google Scholar
• Pant S, Saleh M, Bendell J, et al. Phase 1B dose escalation trial evaluating c-MET inhibitor ARQ 197 plus gemcitabine in patients with advanced solid tumors on schedules refined by in vitro mechanistic studies[abstract 510P]. Ann Oncol 2010;21(Suppl 8):viii167
   Google Scholar
• Rosen LS, Senzer N, Mekhail T, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011;17:7754-64
   PubMed Web of Science ®Google Scholar
• Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ–197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-9
   PubMed Web of Science ®Google Scholar
• Santoro A, Simonelli M, Rodriguez-Lope C, et al. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 2013;108:21-4
   PubMed Web of Science ®Google Scholar
• Goldman JW, Laux I, Chai F, et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012;118:5903-11
   PubMed Web of Science ®Google Scholar
• Puzanov I, Sosman J, Santoro A, et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs 2014; Epub ahead of print
   Google Scholar
• Yamamoto N, Murakami H, Nishina T, et al. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol 2013;24:1653-9
   PubMed Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled Phase 2 study. Lancet Oncol 2013;14:55-63
   PubMed Web of Science ®Google Scholar
• Rimassa L, Porta C, Borbath I, et al. Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Hepatic Oncol 2014;1:181-8
   PubMedGoogle Scholar
• Lu S, Rizzani A, Kolligs FT, et al. Anti-proliferative mechanisms downstream of c-MET of the kinase inhibitor tivantinib (ARQ 197) [abstract 1818]. Hepatology 2013;58(Issue S1):92A-207A
   Google Scholar
• Kanome T, Kadofuku T, Yamaoka T, et al. The novel c-MET inhibitor, ARQ 197, shows additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin/proteasome pathway. Cancer Res 2010;70:abstract 1639
   Google Scholar
• Zhou Y, Zhao C, Gery S, et al. Off target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther 2014;13:134-43
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Kuenzi BM, Luo Y, et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol 2014;9:353-8
   PubMedGoogle Scholar
• Kanteti R, Dhanasingh I, Ichiro Kawada I, et al. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS ONE 2014;9:e105919
   PubMedGoogle Scholar
• Rimassa L, Bruix J, Broggini M, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET – letter. Clin Cancer Res 2013;19:4290
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Novello S, Ramlau R, et al. MET inhibitor tivantinib (ARQ 197) plus erlotinib vs erlotinib plus placebo in NSCLC. Eur J Cancer 2013;49:abstract 3410
   Google Scholar
• Eng C, Hart LL, Severtsev A, et al. A randomized, placebo-controlled, Phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. J Clin Oncol 2013;31(Suppl):abstract 3508
   Google Scholar
• Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-15
   PubMed Web of Science ®Google Scholar
• Rimassa L, Santoro A, Daniele B, et al. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of the Italian centers. Tumori 2014; In press
   Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Camacho LH, Pant S, Saleh MN, et al. Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors. J Clin Oncol 2011;29(Suppl):abstract 3077
   Google Scholar
• Rimassa L, Personeni N, Simonelli M, et al. Tivantinib: a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol 2013;9:153-65
   PubMed Web of Science ®Google Scholar
• Camacho LH, Bendell JC, Pant S, et al. Phase 1b Results of c-MET Inhibitor Tivantinib (ARQ 197) in Combination With Gemcitabine in a Cohort of Patients With Advanced Thoracic Tumors. The 14th World Conference on Lung Cancer 2011; Amsterdam RAI, The Netherlands
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
   PubMed Web of Science ®Google Scholar
• Daniele B, Rimassa L, Borbath I, et al. MET as prognostic factor and therapeutic target in pretreated hepatocellular carcinoma (HCC): final results of a randomized controlled Phase 2 trial (RCT) with tivantinib (ARQ 197). Ann Oncol 2012;23(Suppl 9):ix224-57
   Google Scholar
• Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy (METIV-HCC). Available from: www.clinicaltrials.gov/ct2/show/NCT01755767?term=NCT01755767&rank=1 [Last accessed December 2014]
   Google Scholar
• Fornaro L, Vivaldi C, Caparello C, et al. Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncol 2014;10:285-304
   PubMedGoogle Scholar
• Shao Y, Wu C, Lu L, et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-linesystemic therapy. J Hepatol 2014;60:313-18
   PubMedGoogle Scholar
• Finn RS. Survival after sorafenib: expect the unexpected. J Hepatol 2014;60:243-4
   PubMedGoogle Scholar
• Rimassa L, Porta C, Borbath I, et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). J Clin Oncol 2012;30(Suppl):abstract 4006
   Google Scholar